# Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

> **NCT00024089** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00024089
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024089, "Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00024089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*